- Home
- AIFU vs KPRX Comparison
AIFU vs KPRX Comparison
Compare AIFU & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFU
- KPRX
- Stock Information
- Founded
- AIFU 1998
- KPRX 1998
- Country
- AIFU China
- KPRX United States
- Employees
- AIFU N/A
- KPRX N/A
- Industry
- AIFU
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AIFU
- KPRX Health Care
- Exchange
- AIFU NYSE
- KPRX Nasdaq
- Market Cap
- AIFU 7.3M
- KPRX 8.3M
- IPO Year
- AIFU 2007
- KPRX N/A
- Fundamental
- Price
- AIFU $0.18
- KPRX $3.23
- Analyst Decision
- AIFU
- KPRX Strong Buy
- Analyst Count
- AIFU 0
- KPRX 1
- Target Price
- AIFU N/A
- KPRX $10.00
- AVG Volume (30 Days)
- AIFU 33.7M
- KPRX 13.1K
- Earning Date
- AIFU 05-27-2025
- KPRX 05-09-2025
- Dividend Yield
- AIFU N/A
- KPRX N/A
- EPS Growth
- AIFU 61.54
- KPRX N/A
- EPS
- AIFU 1.15
- KPRX N/A
- Revenue
- AIFU $247,815,758.00
- KPRX $20,000.00
- Revenue This Year
- AIFU N/A
- KPRX N/A
- Revenue Next Year
- AIFU N/A
- KPRX N/A
- P/E Ratio
- AIFU $0.15
- KPRX N/A
- Revenue Growth
- AIFU N/A
- KPRX N/A
- 52 Week Low
- AIFU $0.11
- KPRX $2.51
- 52 Week High
- AIFU $3.64
- KPRX $5.55
- Technical
- Relative Strength Index (RSI)
- AIFU N/A
- KPRX 54.82
- Support Level
- AIFU N/A
- KPRX $2.85
- Resistance Level
- AIFU N/A
- KPRX $3.30
- Average True Range (ATR)
- AIFU 0.00
- KPRX 0.21
- MACD
- AIFU 0.00
- KPRX -0.01
- Stochastic Oscillator
- AIFU 0.00
- KPRX 56.46
About AIFU FANHUA INC SPON ADS EACH REPR 20 ORD SHS
AIFU Inc is an independent financial services provider in China. It offer end-to-end business solutions spanning compliance, technology, products, services, operations, capital flow, and professional training. It connects customers with insurance protection, retirement planning, health management, asset management, and family governance services.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.